Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Ionizing radiation emitter

DRUG CLASS:

Ionizing radiation emitter

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

177Lu-satetraxetan-lilotomab (4)

lutetium Lu 177 vipivotide tetraxetan (4)

ibritumomab tiuxetan (3)

177Lu-FAP-2286 (2)

radium Ra-223 dichloride (2)

lutetium Lu 177 dotatate (1)

111In-DOTA-h11B6 (0)

177Lu HTK03170 (0)

177Lu-BiOncoFAP (0)

177Lu-DTPA-SC16 (0)

177Lu-DTPA-omburtamab (0)

177Lu-EB-LM3 (0)

177Lu-LNC1004 (0)

177Lu-OncoFAP-23 (0)

177Lu-P17-087 (0)

177Lu-P17-088 (0)

177Lu-PSMA-EB-01 (0)

177Lu-PSMA-R2 (0)

177Lu-TE-1132 (0)

177Lu-rhPSMA-10.1 (0)

177LuFF-10158 (0)

BAY 3546828 (0)

Actinium-225 conjugated to daratumumab (0)

AvidinOx/Lu-177 DOTA biotin (0)

BAY 3563254 (0)

iodine I 131 tositumomab (0)

CLDN18.2 targeted radiopharmaceutical therapeutic (0)

iodine I 131 derlotuximab (0)

samarium-153 DOTMP (0)

DARPin-conjugated radioligand therapeutic (0)

DR-18621-GBMF (0)

64Cu-Dotatate (0)

EGFR sdAb based radiotherapy (0)

GPC3 targeted radiopharmaceutical therapy (0)

177Lu-DOTA-NNV003 (0)

Lu 177 PSMA I&T (0)

Lutetium-177 PNT6555 (0)

Lutetium-177-PEG-αvβ3-IAC (0)

epratuzumab Y-90 (0)

166 holmium poliglusam (0)

PSMA targeted radiopharmaceutical therapeutic (0)

lutetium-177 DOTA satoreotide (0)

67Cu MeCOSar octreotate (0)

177Lu-edotreotide (0)

palladium-103 (0)

Undisclosed cancer therapeutic (0)

Undisclosed next gen prostate cancer therapeutic (0)

Undisclosed radiopharmaceutical (0)

actinium-225 radio-conjugate theranostic (0)

yttrium Y-90 clivatuzumab tetraxetan (0)

radiolabelled olaratumab (0)

sodium iodide I 131 (0)

›

CD20 positive	Follicular Lymphoma	CD20 positive	Follicular Lymphoma	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1	rituximab + ibritumomab tiuxetan Sensitive: A1 - Approval rituximab + ibritumomab tiuxetan Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1	ibritumomab tiuxetan Sensitive: A1 - Approval ibritumomab tiuxetan Sensitive : A1
FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	ibritumomab tiuxetan Sensitive: A2 - Guideline ibritumomab tiuxetan Sensitive : A2	ibritumomab tiuxetan Sensitive: A2 - Guideline ibritumomab tiuxetan Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B
No biomarker	Lymphoplasmacytic Lymphoma	No biomarker	Lymphoplasmacytic Lymphoma	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B	CLR 131 Sensitive: B - Late Trials CLR 131 Sensitive : B
SSTR positive	Neuroendocrine Tumor	SSTR positive	Neuroendocrine Tumor	lutetium Lu 177 dotatate Sensitive: B - Late Trials lutetium Lu 177 dotatate Sensitive : B	lutetium Lu 177 dotatate Sensitive: B - Late Trials lutetium Lu 177 dotatate Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3
TMPRSS2-ERG fusion	Prostate Cancer	TMPRSS2-ERG fusion	Prostate Cancer	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3
RB deletion	Prostate Cancer	RB deletion	Prostate Cancer	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3	radium Ra-223 dichloride Resistant: C3 – Early Trials radium Ra-223 dichloride Resistant : C3
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4	enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4
FAP expression	Sarcoma	FAP expression	Sarcoma	177Lu-FAP-2286 Sensitive: D – Preclinical 177Lu-FAP-2286 Sensitive : D	177Lu-FAP-2286 Sensitive: D – Preclinical 177Lu-FAP-2286 Sensitive : D
FAP expression	Pancreatic Cancer	FAP expression	Pancreatic Cancer	177Lu-FAP-2286 Sensitive: D – Preclinical 177Lu-FAP-2286 Sensitive : D	177Lu-FAP-2286 Sensitive: D – Preclinical 177Lu-FAP-2286 Sensitive : D
ERBB3 expression	Renal Cell Carcinoma	ERBB3 expression	Renal Cell Carcinoma	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D
ERBB3 expression	Prostate Cancer	ERBB3 expression	Prostate Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D
ERBB3 expression	Colorectal Cancer	ERBB3 expression	Colorectal Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D
ERBB3 expression	Ovarian Cancer	ERBB3 expression	Ovarian Cancer	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D	177Lu-satetraxetan-lilotomab Sensitive: D – Preclinical 177Lu-satetraxetan-lilotomab Sensitive : D